Kidswell Bio (4584) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue increased substantially during the period, and the operating loss turned profitable, primarily due to a decline in the SG&A ratio; however, the company remained in a final loss position because of the burden of non-operating expenses. Revenue was ¥50.2B (¥30.4B in the same period of the previous year, YoY +65.3%), Operating Income was ¥0.8B (¥-1.4B in the previous year), Ordinary Income was ¥-1.3B (¥-1.6B in the previous year), and Net Income attributable to owners of the parent was ¥-1.4B (¥-1.9B in the previous year). The return to operating profitability was primarily attributable to the operating leverage effect from a significant decline in the SG&A ratio, although the gross profit margin declined, indicating that the quality of the revenue growth was not uniform.

Factors Affecting Performance

【Revenue】Revenue increased substantially to ¥50.2B, representing a year-on-year increase of +65.3%. The company operates as a single segment, the Pharmaceutical Development Business, and progress in development projects and contracted projects appears to have driven the revenue increase. Cost of sales increased by 83.9%, from ¥3.9B to ¥6.8B, exceeding the growth in revenue; consequently, the gross profit margin declined to 26.5%, approximately 7.5pt below the previous year’s 34.0%.

【Profit and Loss】SG&A expenses increased by only +6.6% year on year, and the SG&A ratio declined to 24.8% from 38.5% in the previous year, a decrease of approximately 13.7pt. This led the turnaround to Operating Income of ¥0.8B (¥-1.4B in the previous year). Meanwhile, non-operating expenses of ¥2.3B (including interest expense of ¥0.3B and fees paid of ¥0.8B) exceeded Operating Income, leaving Ordinary Income at ¥-1.3B. Even after adding extraordinary income of ¥0.1B, the loss before tax was ¥-1.2B, resulting in Net Income of ¥-1.4B. Although the company progressed toward operating profitability alongside revenue growth, non-operating expenses offset the improvement in profit. Therefore, it cannot be characterized simply as revenue growth accompanied by profit growth; rather, the company is at a stage of revenue growth and a return to operating profitability, while Ordinary Income and Net Income remain in the red.

Segment Analysis

The company operates as a single segment, the Pharmaceutical Development Business, and segment-level disclosure has been omitted.

Key Financial Indicators

【Profitability】The Operating Profit Margin improved to 1.7% from △4.5% in the previous year, but remained below the general profitability benchmark of 5%. The gross profit margin declined to 26.5% from 34.0% in the previous year, indicating that revenue growth has not necessarily been accompanied by improved profitability. Research and development expenses were ¥6.7B (13.4% of revenue), down from 17.8% in the previous year, although the absolute amount increased by +23.9% year on year.【Cash Quality】Cash and deposits were ¥37.8B, accounting for 59.9% of total assets, and increased by +26.4% year on year. Meanwhile, accounts receivable declined by △62.6% year on year to ¥4.7B, suggesting that collection progress or changes in the revenue mix may have contributed to the increase in cash.【Investment Efficiency】Annualized ROE was △9.9%, primarily due to the loss in the net profit margin. High financial leverage is putting downward pressure on ROE during the loss-making phase.【Financial Soundness】The Equity Ratio improved to 30.5% from 19.1% in the previous year, but long-term borrowings increased substantially to ¥22.0B from ¥6.8B in the previous year, and the D/E ratio remains high relative to the capital base. The current ratio was a robust 306.7%, indicating good short-term liquidity.

Cash Flow Analysis

Although detailed disclosure of the cash flow statement is unavailable, cash flow trends can be inferred from changes in the balance sheet. Cash and deposits increased by ¥7.9B (+26.4%) year on year to ¥37.8B, while the increase in long-term borrowings of +¥15.2B to ¥22.0B appears to have contributed to funding. Meanwhile, accounts receivable declined by △¥7.9B, and contract liabilities (advance payments) declined by △¥17.6B, suggesting that collections through operating activities and the recognition of deferred revenue progressed. Work in progress also declined by △¥8.6B, indicating that improvements in inventory turnover or changes in development plans may have affected capital efficiency. Overall, the increase in cash balances was supported by borrowing-based financing and working capital compression. It is important to note that, in addition to the return to operating profitability, financing activities are supporting the cash level.

Quality of Earnings

Operating Income of ¥0.8B reflects an improvement in recurring business activities; however, non-operating expenses of ¥2.3B (including interest expense of ¥0.3B and fees paid of ¥0.8B) exceeded this amount, leaving Ordinary Income at a loss of ¥-1.3B. This factor affects the quality of earnings. Extraordinary income of ¥0.1B appears to consist primarily of gains on the expiration of stock acquisition rights and similar items; its scale was small and its impact on profit and loss was limited. Comprehensive Income was ¥-1.7B, broadly close to the Net Loss attributable to owners of the parent of ¥-1.4B, with a △¥0.3B valuation difference on other securities accounting for the variance. The decline in the gross profit margin coexisted with an increase in the absolute amount of research and development expenses, requiring continued monitoring of accruals related to profitability behind the revenue growth.

Shareholder Returns

The dividend forecast was ¥0 per share for both Q2 and the Full Year, and the no-dividend policy remains in place. As Net Loss attributable to owners of the parent was ¥1.4B, the Payout Ratio is not applicable for calculation. The capital allocation policy of maintaining cash and deposits of ¥37.8B while allocating funds to research and development investment and debt repayment is consistent with the continuation of no dividend payments.

Risk Factors

1. Expansion of financial leverage: Long-term borrowings increased by +223.1% year on year to ¥22.0B, and the D/E ratio is high relative to the capital base. With the Operating Profit Margin remaining low at 1.7%, increased interest expenses could weigh on the improvement of final profit and loss.

2. Decline in gross profit margin and concentration in a single business: The gross profit margin declined by approximately 7.5pt year on year to 26.5%, and revenue growth has not been accompanied by improved profitability. As the company operates as a single segment, the Pharmaceutical Development Business, development progress and decisions by alliance partners have a concentrated impact on performance.

3. Decline in contract liabilities: Contract liabilities (advance payments) were ¥12.1B, down ¥17.6B from ¥29.7B in the previous year, indicating that the recognition of deferred revenue is proceeding ahead of new inflows. If the accumulation of new contracts and alliances is weak, this could affect future revenue recognition.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Within an industry where losses tend to be chronic, the company’s Operating Profit Margin and Net Profit Margin are both substantially above the median.

Growth and Capital Efficiency

The Revenue Growth Rate was substantially above the industry median, which was in negative territory, demonstrating a high rate of revenue growth within the industry.

※Source: Compiled by the Company

Key Points from the Financial Results

1. Operating profit turned positive at ¥0.8B due to a 65.3% increase in revenue and a significant decline in the SG&A ratio; however, the gross profit margin declined by approximately 7.5pt, requiring attention to the quality of the revenue growth.

2. Non-operating expenses of ¥2.3B exceeded operating profit, and losses at the Ordinary Income and Net Income levels continued. Absorbing financial costs, including interest expenses, will be a key focus going forward.

3. Although the D/E ratio increased to a high level relative to the capital base due to the increase in long-term borrowings, cash and deposits remained at ¥37.8B and short-term liquidity was robust, with a current ratio of 306.7%.

---

This report is a financial results analysis document automatically generated by AI based on XBRL financial results summary data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed financial results data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---